169 related articles for article (PubMed ID: 34150958)
1. Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.
Byrgazov K; Lind T; Rasmusson AJ; Andersson C; Slipicevic A; Lehmann F; Gullbo J; Melhus H; Larsson R; Fryknäs M
Bone Rep; 2021 Dec; 15():101098. PubMed ID: 34150958
[TBL] [Abstract][Full Text] [Related]
2. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.
Gebraad A; Ohlsbom R; Miettinen JJ; Emeh P; Pakarinen TK; Manninen M; Eskelinen A; Kuismanen K; Slipicevic A; Lehmann F; Nupponen NN; Heckman CA; Miettinen S
Cells; 2022 May; 11(9):. PubMed ID: 35563880
[TBL] [Abstract][Full Text] [Related]
3. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma.
Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M
J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623
[TBL] [Abstract][Full Text] [Related]
6. Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S
Drugs; 2021 Jun; 81(8):963-969. PubMed ID: 33961277
[TBL] [Abstract][Full Text] [Related]
7. Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Wickström M; Nygren P; Larsson R; Harmenberg J; Lindberg J; Sjöberg P; Jerling M; Lehmann F; Richardson P; Anderson K; Chauhan D; Gullbo J
Oncotarget; 2017 Sep; 8(39):66641-66655. PubMed ID: 29029544
[TBL] [Abstract][Full Text] [Related]
8. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of melflufen (J1)in lymphoma.
Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
[TBL] [Abstract][Full Text] [Related]
10. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
11. Melflufen, a peptide-conjugated alkylator, is an efficient anti-neo-plastic drug in breast cancer cell lines.
Schepsky A; Traustadottir GA; Joelsson JP; Ingthorsson S; Kricker J; Bergthorsson JT; Asbjarnarson A; Gudjonsson T; Nupponen N; Slipicevic A; Lehmann F; Gudjonsson T
Cancer Med; 2020 Sep; 9(18):6726-6738. PubMed ID: 32717133
[TBL] [Abstract][Full Text] [Related]
12. Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma.
Mateos MV; Bladé J; Bringhen S; Ocio EM; Efebera Y; Pour L; Gay F; Sonneveld P; Gullbo J; Richardson PG
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32992506
[TBL] [Abstract][Full Text] [Related]
13. Melflufen for the treatment of multiple myeloma.
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
[TBL] [Abstract][Full Text] [Related]
14. Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O; Mateos MV; Efebera YA; Paner A; Larocca A; Rodríguez-Otero P; Leleu X; Richardson PG
Drugs Today (Barc); 2022 Aug; 58(8):407-423. PubMed ID: 35983927
[TBL] [Abstract][Full Text] [Related]
15. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
16. The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death.
Flanagan K; Kumari R; Miettinen JJ; Haney SL; Varney ML; Williams JT; Majumder MM; Suvela M; Slipicevic A; Lehmann F; Nupponen NN; Holstein SA; Heckman CA
Hemasphere; 2022 Mar; 6(3):e687. PubMed ID: 35243210
[TBL] [Abstract][Full Text] [Related]
17. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
18. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
19. IL-1β differently stimulates proliferation and multinucleation of distinct mouse bone marrow osteoclast precursor subsets.
Cao Y; Jansen ID; Sprangers S; Stap J; Leenen PJ; Everts V; de Vries TJ
J Leukoc Biol; 2016 Sep; 100(3):513-23. PubMed ID: 26957213
[TBL] [Abstract][Full Text] [Related]
20. A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action.
Westermark U; Diao Y; Fasth KJ; Färnegårdh M; Färnegårdh K; Hammer K; Lehmann F; Acs K; Svensson Gelius S
Biochem Biophys Res Commun; 2023 May; 656():122-130. PubMed ID: 37032581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
